Literature DB >> 1741647

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s.

E J Schweitzer1, A J Matas, K J Gillingham, W D Payne, P F Gores, D L Dunn, D E Sutherland, J S Najarian.   

Abstract

A variety of refinements in the care of kidney transplant recipients have been instituted over the past decade. The authors studied the overall impact of these refinements on kidney allograft losses at a single institution. To do this they compared the causes and rates of graft loss for primary kidney transplants in the 1970s (January 1, 1970 to December 31, 1979; n = 1012; 657 nondiabetics, 355 diabetics; 617 living donors, 395 cadaver donors) versus the 1980s (January 1, 1980 to December 31, 1989; n = 1,384; 756 nondiabetics, 628 diabetics; 740 living donors, 644 cadaver donors). Overall patient survival improved significantly, with rates at 1, 5, and 10 years of 94%, 84%, and 68% for the 1980s, compared with 86%, 69%, and 57% for the 1970s (p less than 0.001). Actuarial graft survival also improved significantly, with rates at 1, 5, and 10 years of 86%, 71%, and 52% for the 1980s, compared with 73%, 58%, and 43% for the 1970s (p less than 0.001). This improvement occurred even though there were proportionately more cadaver donors and diabetic recipients in the 1980s. For both decades combined, 24% of the lost grafts were due to chronic rejection, 18% to cardiovascular causes of death with function, 13% to infectious causes of death with function, and 11% to acute rejection. The overall gain in graft survival rates in the 1980s was principally due to fewer cases of acute rejection and fewer infectious deaths. Improvement in graft survival due to the two leading causes--chronic rejection and cardiovascular causes of death--was relatively small, if any. These data indicate that future kidney transplantation research should emphasize prevention of chronic rejection and cardiovascular death.

Entities:  

Mesh:

Year:  1991        PMID: 1741647      PMCID: PMC1358492          DOI: 10.1097/00000658-199112000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  36 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  The late results of renal transplantation and the importance of chronic rejection as a cause of graft loss.

Authors:  M C Foster; P W Wenham; P A Rowe; R P Burden; A G Morgan; R E Cotton; R W Blamey
Journal:  Ann R Coll Surg Engl       Date:  1989-01       Impact factor: 1.891

3.  Causes of death in kidney transplant recipients: 1970 to present.

Authors:  B A Dlugosz; P N Bretan; A C Novick; D R Steinmuller; S B Streem; K Badwar; R M Woodard
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

4.  Long-term clinical studies of high-risk renal retransplant recipients given total lymphoid irradiation.

Authors:  D B Kaufman; T H Kim; S Slavin; J S Najarian; D E Sutherland
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

5.  Is chronic renal transplant rejection a non-immunological phenomenon?

Authors:  J Feehally; K P Harris; S E Bennett; J Walls
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

6.  Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies.

Authors: 
Journal:  N Engl J Med       Date:  1986-03-27       Impact factor: 91.245

7.  A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

Authors:  H H Balfour; B A Chace; J T Stapleton; R L Simmons; D S Fryd
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

8.  Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection.

Authors:  P Sweny; D C Wheeler; S F Lui; N S Amin; M A Barradas; J Y Jeremy; D P Mikhailidis; Z Varghese; O N Fernando; J F Moorhead
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

9.  Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors.

Authors:  J S Najarian; R L Simmons; R M Condie; E J Thompson; D S Fryd; R J Howard; A J Matas; D E Sutherland; R M Ferguson; J R Schmidtke
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

10.  A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.

Authors:  J S Najarian; D S Fryd; M Strand; D M Canafax; N L Ascher; W D Payne; R L Simmons; D E Sutherland
Journal:  Ann Surg       Date:  1985-02       Impact factor: 12.969

View more
  13 in total

1.  The effect of different immunosuppressants on alloantigen dependent and independent factors involved in the development of chronic rejection in an animal model.

Authors:  O Cole; K Rigg; M Shehata
Journal:  Ann R Coll Surg Engl       Date:  2001-07       Impact factor: 1.891

2.  Antibodies against mesangial cells and their secretory products in chronic renal allograft rejection in the rat.

Authors:  L C Paul; J Muralidharan; S A Muzaffar; E H Manting; J F Valentin; E de Heer; M Kashgarian
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients.

Authors:  Larissa Kerecuk; Judy Taylor; Godfrey Clark
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

Review 4.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection.

Authors:  A J Matas; A Humar; W D Payne; K J Gillingham; D L Dunn; D E Sutherland; J S Najarian
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

Review 6.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

Authors:  B Fulton; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 7.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Human kidney graft survival correlates with structural parameters in baseline biopsies: a quantitative observational cohort study with more than 14 years' follow-up.

Authors:  Anne R Ellingsen; Kaj A Jørgensen; Ruth Østerby; Steffen E Petersen; Svend Juul; Niels Marcussen; Jens R Nyengaard
Journal:  Virchows Arch       Date:  2020-09-28       Impact factor: 4.064

Review 9.  Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.

Authors:  Roberto Marcén
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

10.  Causes of kidney allograft loss in a large pediatric population at a single center.

Authors:  B M Chavers; E M Kim; A J Matas; K J Gillingham; J S Najarian; S M Mauer
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.